AT Venture Center

AT Venture Center (ATVC) is a specialized venture studio and drug development organization focused exclusively on Ataxia Telangiectasia (A-T), a rare genetic neurodegenerative disorder. Established as an initiative of the A-T Children's Project, the center functions by identifying promising academic research and translating it into clinical-stage therapeutic programs. Its portfolio includes diverse approaches such as antisense oligonucleotides (ASOs) and gene therapies designed to restore ATM protein function. By providing seed funding and drug development expertise, ATVC aims to de-risk early-stage assets to attract further investment or partnership. The organization serves as a critical bridge between basic science and the delivery of transformative medicines to patients.